TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.
Type
Public
HQ
Valbonne, FR
Founded
2001
Size (employees)
48 (est)
Website
txcell.com
TxCell was founded in 2001 and is headquartered in Valbonne, FR

Key People at TxCell

Francois Meyer

Francois Meyer

CEO

TxCell Office Locations

TxCell has an office in Valbonne
Valbonne, FR (HQ)
Allée De La Nertière

TxCell Data and Metrics

TxCell Financial Metrics

Numbers are in €, EUR

Market capitalization (12-May-2017)

24.7 m

Closing share price (12-May-2017)

1.9
TxCell's current market capitalization is €24.7 m.

TxCell Market Value History

TxCell Online and Social Media Presence

TxCell Company Life and Culture

You may also be interested in